基于单细胞测序与数字PCR筛查单核细胞差异基因集对脓毒症早期诊断的临床意义
本研究纳入2020年6月至2021年3月广东省人民医院收治的脓毒症患者,提取外周血单个核细胞,用单细胞测序和拟时序分析验证NEAT1+CD163+单核细胞为脓毒症特征亚群,并筛选出22个差异基因;经数字PCR验证后构建7基因差异集(BATF、JUNB、CEACAM4、GNA15、C3AR1、TGFB1、MTCH1)。GEO外部验证显示该基因集在GSE154918和GSE133822中对早期脓毒症的AUC分别为0.993(95%CI 0.980-1.000)和0.944(95%CI 0.873-1.000)。该基因集可能为脓毒症早期诊断提供新思路,但当前仅为生物信息学与体外验证结果,尚未转化为床旁快速检测。
要点
- 单细胞测序与拟时序分析证实NEAT1+CD163+单核细胞是脓毒症病理过程中的特征亚群,其分化在脓毒症早期即与其他亚群显著不同。
- 从NEAT1+CD163+单核细胞中筛选出22个脓毒症相关差异基因,经数字PCR验证后最终构建7基因差异集:BATF、JUNB、CEACAM4、GNA15、C3AR1、TGFB1、MTCH1。
- GEO数据库GSE154918中脓毒症组7基因表达均显著高于健康对照(均P<0.05),GSVA富集评分0.38±0.04 vs. -0.44±0.02(P<0.01),AUC 0.993(95%CI 0.980-1.000)。
- GSE133822中仅BATF、CEACAM4、GNA15、C3AR1表达显著高于健康对照(均P<0.05),JUNB、TGFB1、MTCH1无统计学差异,GSVA评分0.56±0.02 vs. 0.20±0.05(P<0.01),AUC 0.944(95%CI 0.873-1.000)。
- C9orf95基因在GSE154918和GSE133822中无数据,外部验证时被排除;该基因集目前仅为生物标志物研究,尚未提供床旁检测方法或诊断阈值。
适用人群与场景
- 研究纳入2020年6月至2021年3月广东省人民医院收治的脓毒症患者,提取外周血单个核细胞(PBMC)进行验证。
- 外部验证使用GEO数据库GSE154918和GSE133822中脓毒症组与健康对照组数据。
- 原文未提及急诊、ICU或院前场景的具体适用人群、纳入排除标准及病情阶段。
诊断标准与关键阈值
- 原文未提及脓毒症的临床诊断标准名称、各项条件及界值。
- 原文未提及单核细胞差异基因集用于早期诊断的启动阈值或截断值。
处置流程与药物剂量
- 原文未提及基于该差异基因集的床旁处置流程或药物剂量方案。
红旗征与不能漏的情况
- 原文未提及红旗征或不能漏诊的情况及相应处理。
研究设计与关键结果
- 研究类型:实验验证与生物信息学分析研究,纳入广东省人民医院脓毒症患者外周血单个核细胞,并用GEO数据库GSE154918和GSE133822进行外部验证;原文未提及样本量及中心数。
- 单细胞测序与拟时序分析显示NEAT1+CD163+单核细胞分化在脓毒症早期与其他亚群显著不同,验证其为脓毒症病理过程的特征亚群。
- 从NEAT1+CD163+单核细胞基因表达中筛选出22个脓毒症相关差异基因,经数字PCR验证后构建7基因差异集:BATF、JUNB、CEACAM4、GNA15、C3AR1、TGFB1、MTCH1。
- GSE154918中脓毒症组BATF、JUNB、CEACAM4、GNA15、C3AR1、TGFB1、MTCH1表达均显著高于健康对照(均P<0.05),GSVA富集评分0.38±0.04 vs. -0.44±0.02(P<0.01),ROC曲线AUC 0.993(95%CI 0.980-1.000)。
- GSE133822中脓毒症组BATF、CEACAM4、GNA15、C3AR1表达显著高于健康对照(均P<0.05),JUNB、TGFB1、MTCH1两组间无统计学差异;GSVA评分0.56±0.02 vs. 0.20±0.05(P<0.01),AUC 0.944(95%CI 0.873-1.000)。
- C9orf95基因在GSE154918和GSE133822中无数据,外部验证时被排除。
证据类型、等级与局限
- 证据类型:实验验证与生物信息学分析研究(单细胞测序、数字PCR、GEO数据库外部验证),原文未给出证据等级或推荐强度。
- 局限:原文未提及样本量、中心数及前瞻性临床验证;外部验证仅使用GEO数据库数据,C9orf95因无数据被排除,GSE133822中JUNB、TGFB1、MTCH1未显示统计学差异,基因集诊断阈值未在原文中给出。
对床旁实践的改变
- 该研究提示NEAT1+CD163+单核细胞及7基因差异集(BATF、JUNB、CEACAM4、GNA15、C3AR1、TGFB1、MTCH1)对早期脓毒症具有可靠诊断价值,但仅为生物信息学与体外验证结果,尚不能改变急诊或ICU当前脓毒症早期诊断流程。
- 原文未提供床旁快速检测方法、诊断阈值或适用人群,临床实践中不应将上述基因集作为脓毒症诊断或排除依据。
- 常见陷阱:GSE133822中JUNB、TGFB1、MTCH1在脓毒症组与健康对照组间无统计学差异,提示不同数据集中基因集表现不完全一致,不能将GSE154918的高AUC直接外推至所有临床场景。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To verify the specific differentiated subsets of monocytes in sepsis, and to screen and construct the differential gene set of monocytes used for early diagnosis of sepsis.
METHODS: Patients with sepsis admitted to Guangdong Provincial People's Hospital from June 2020 to March 2021 were enrolled, and peripheral blood mononuclear cells (PBMC) were extracted. Single-cell sequencing technology and pseudo-time analysis were used to verify the differential subsets of monocytes. Bioinformatics methods were used to analyze the expression of genes in differential subsets of monocytes and screen out differential genes for the preliminary construction of a candidate differential gene set. The digital polymerase chain reaction (PCR) technology was used to verify the candidate differential genes in PBMC of sepsis patients and sepsis human myeloid leukemia mononuclear cells (THP-1) models, and the Venn diagram was used to construct the final differential gene set of monocytes. Gene Expression Omnibus (GEO) database was used to validate the differential gene set of monocytes.
RESULTS: (1) The results of cell annotation and pseudo-time analysis showed that the differentiation of NEAT1+CD163+ monocyte occurred in the early stage of sepsis was significantly different from other subsets, which validated that NEAT1+CD163+ monocyte was the characteristic subset in the pathological process of sepsis. (2) Twenty-two differential genes related to sepsis were screened out from the gene expression of NEAT1+CD163+ monocyte. After further verification by digital PCR, basic leucine zipper ATF-like transcription factor (BATF), JUNB proto-oncogene, carcinoembryonic antigen-related cell adhesion molecule 4 (CEACAM4), chromosome 9 open reading frame 95 (C9orf95), G protein subunit alpha 15 (GNA15), complement C3a receptor 1 (C3AR1), transforming growth factor beta 1 (TGFB1) and mitochondrial carrier homolog 1 (MTCH1) were screened out to construct the final differential gene set of monocytes. (3) The external validation results showed that C9orf95 gene had no data in GSE154918 and GSE133822 from GEO, it was excluded during validation. In GSE154918, the expressions of BATF, JUNB, CEACAM4, GNA15, C3AR1, TGFB1, and MTCH1 in the sepsis group were significantly higher than those in the healthy control group (log2expression level: BATF was 12.78±0.08 vs. 11.39±0.35, JUNB was 16.88±0.07 vs. 16.04±0.03, CEACAM4 was 14.73±0.08 vs. 13.77±0.05, GNA15 was 13.16±0.06 vs. 12.30±0.04, C3AR1 was 14.62±0.13 vs. 12.87±0.05, TGFB1 was 16.95±0.05 vs. 16.57±0.36, MTCH1 was 14.80±0.02 vs. 14.61±0.15, all P < 0.05). In GSE133822, the expressions of BATF, CEACAM4, GNA15, and C3AR1 in the sepsis group were significantly higher than those in the health control group (log2expression level: BATF was 8.66±0.16 vs. 7.92±0.14, CEACAM4 was 9.20±0.16 vs. 8.36±0.20, GNA15 was 10.66±0.18 vs. 10.13±0.16, C3AR1 was 11.49±0.27 vs. 10.48±0.16, all P < 0.05), while the expressions of JUNB, TGFB1, and MTCH1 were not statistically different between two groups. The results of gene set variation analysis (GSVA) showed that the enrichment scores of monocytes differential gene set of sepsis group were significantly higher than those of the healthy control group in both GSE154918 (0.38±0.04 vs. -0.44±0.02) and GSE133822 (0.56±0.02 vs. 0.20±0.05, both P < 0.01). Receiver operator characteristic curve (ROC curve) analysis showed that the differential gene set of monocytes had a reliable diagnostic value for early sepsis with the area under ROC curve (AUC) of 0.993 [95% confidence interval (95%CI) was 0.980-1.000] in GSE154918 and 0.944 (95%CI was 0.873-1.000) in GSE133822.
CONCLUSIONS: A differential gene set of monocytes (BATF, JUNB, CEACAM4, GNA15, C3AR1, TGFB1, and MTCH1) screened out by single-cell sequencing and digital PCR technology has a reliable diagnostic value for the early sepsis, and may provide a new idea for the early diagnosis of sepsis.
参考来源
- Cai G, Zhou Y, Wen M, et al. [Clinical importance of screening differential gene set of monocytes based on single-cell sequencing and digital polymerase chain reaction technology for early diagnosis of sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34412744. doi:10.3760/cma.j.cn121430-20210607-00832
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。